Publications
Owyong M, Chou J, van den Bijgaart RJ, Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C, Hadler-Olsen E, Headley M, Lin C, Wang CY, Sagi I, Werb Z, Plaks V. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life science alliance. 2019. PMID: 31727800
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019. PMID: 31725351
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic oncology. 2019. PMID: 31734020
Chari A, Vogl DT, Jagannath S. Selinexor for Refractory Multiple Myeloma. Reply. The New England journal of medicine. 2019. PMID: 31722163
Kelly L. Schoenbeck, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Karin L. Gaensler, Andrew D. Leavitt, Aaron C. Logan, Gabriel N. Mannis, Rebecca L. Olin, Giselle Salmasi, Peter H. Sayre, Neil P. Shah, Anand Dhruva, Chloe E. Atreya, Catherine C. Smith. Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution. Blood. 2019. PMID:
CHI-HENG WU, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z. Ai. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. Blood. 2019. PMID:
David A. Solomon, Huimin Geng, Raymond A. Sobel, Lakshmi Subbaraj, Mazie Tsang, James L. Rubenstein. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood. 2019. PMID:
Courtney D. DiNardo, Rebecca Olin, Jo Ishizawa, Hiroyuki Sumi, Jingdong Xie, Kazunobu Kato, Prasanna Kumar, Michael Andreeff. A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood. 2019. PMID:
Jordon Jaggers, Heidi D. Klepin, Tanya M. Wildes, Rebecca L. Olin, Andrew S. Artz, Sarah A Wall, Samantha Jaglowski, Basem M. William, Don M. Benson, Ashley E. Rosko. Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood. 2019. PMID:
Rebecca L. Olin, Caitrin Fretham, Marcelo C. Pasquini, Mukta Arora, Vijaya R. Bhatt, Benjamin Derman, Sergio A Giralt, Li-Wen Huang, Thuy T. Koll, Sang Mee Lee, Richard J Lin, Linda Pang, Uday Popat, Daniel J. Weisdorf, Andrew S. Artz. Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood. 2019. PMID:
Amy Burd, Ross L. Levine, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael W. Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark Litzow, James M. Foran, Tara L. Lin, Brian J Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison R. Walker, Vu H. Duong, Robert H. Collins, Nyla A. Heerema, Jo-Anne Vergilio, TIm Brennan, Christine Vietz, Molly Vittorio, Leonard Rosenberg, Sonja Marcus, Ashley Owen Yocum, Mona Stefanos, Brian J. Druker, John C. Byrd. Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. Blood. 2019. PMID:
Benjamin Demaree, Cyrille Delley, Cheryl Peretz, Harish Vasudevan, David Ruff, Aik Ooi, Catherine C. Smith, Adam Abate. Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones. Blood. 2019. PMID:
Naval G. Daver, Jacqueline S Garcia, Brian A Jonas, Kevin R Kelly, Sarit Assouline, Joseph M Brandwein, Pierre Fenaux, Rebecca L. Olin, Giovanni Martinelli, Stefania Paolini, Arnaud Pigneux, Daniel A Pollyea, Bayard L Powell, Gail J. Roboz, Agostino Tafuri, Norbert Vey, Giuseppe Visani, Karen W.L. Yee, Monique Dail, Cherie Green, Whitney P Kirschbrown, Wan-Jen Hong, Marion G Ott, Maika Onishi, Jue Wang, Marina Y Konopleva, Michael Andreeff. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood. 2019. PMID:
Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019. PMID:
Varun Mittal, Mimi Lo, Lloyd E. Damon, Karin L. Gaensler, Thomas G. Martin, Rebecca L. Olin, Catherine C. Smith, Aaron C. Logan. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 2019. PMID:
Catherine C. Smith, Mark J. Levis, Alexander E. Perl, Giovanni Martinelli, Andreas Neubauer, Ellin Berman, Pau Montesinos, Maria R. Baer, Richard A. Larson, Wen-Chien Chou, Hisayuki Yokoyama, Christian Recher, Sung-Soo Yoon, Jason E. Hill, Matt Rosales, Erkut Bahceci. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood. 2019. PMID:
Cheryl A Cohler Peretz, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Chunxiao Zhang, Mark J. Levis, Alexander E. Perl, Anskar Yu Hung Leung, Catherine C. Smith. Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib. Blood. 2019. PMID:
Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nature reviews. Drug discovery. 2019. PMID: 31712683
Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot and Feasibility Studies. 2019. PMID: 31720002
Smith MR, Mehra M, Nair S, Lawson J, Small EJ. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer. 2019. PMID: 31980408